Literature DB >> 22930488

Etomidate in the emergency management of hypercortisolemia.

Lip Min Soh, Kirun Gunganah, Scott A Akker, Philip Jones, Hasanin Khachi, Kumbirai Dodzo, William M Drake.   

Abstract

We describe a protocol for etomidate infusion for the emergency management of hypercortisolemia. Etomidate is commenced at 2.5 mg/h and titrated subsequently according to cortisol levels. It is well tolerated without any sedative effects and can be administered safely via peripheral access for use in the general ward setting.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22930488     DOI： 10.1530/EJE-12-0698

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


  8 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.

Authors:  Ervin Pejo; Peter Santer; Spencer Jeffrey; Hilary Gallin; S Shaukat Husain; Douglas E Raines
Journal:  Anesthesiology       Date:  2014-08       Impact factor: 7.892

Review 3.  Role of "old" pharmacological agents in the treatment of Cushing's syndrome.

Authors:  A G Ambrogio; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2016-04-16       Impact factor: 4.256

Review 4.  Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.

Authors:  Iosif A Mendichovszky; Andrew S Powlson; Roido Manavaki; Franklin I Aigbirhio; Heok Cheow; John R Buscombe; Mark Gurnell; Fiona J Gilbert
Journal:  Diagnostics (Basel)       Date:  2016-11-18

Review 5.  Update on medical treatment for Cushing's disease.

Authors:  Daniel Cuevas-Ramos; Dawn Shao Ting Lim; Maria Fleseriu
Journal:  Clin Diabetes Endocrinol       Date:  2016-09-13

Review 6.  Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Authors:  Andrea Pence; Megan McGrath; Stephanie L Lee; Douglas E Raines
Journal:  Ther Adv Endocrinol Metab       Date:  2022-02-14       Impact factor: 3.565

7.  Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma.

Authors:  Alfredo Adolfo Reza-Albarrán; Gerson Geovany Andino Ríos; Laura Gabriela Gómez Herrera
Journal:  Clin Case Rep       Date:  2018-03-12

8.  Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Authors:  Agnieszka Łebek-Szatańska; Karolina M Nowak; Wojciech Zgliczyński; Elżbieta Baum; Agnieszka Żyłka; Lucyna Papierska
Journal:  Ther Adv Endocrinol Metab       Date:  2019-02-08       Impact factor: 3.565
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.